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It is unclear which quality of life instruments have thus 
far been used in eczema trials. Therefore, we aimed to 
identify these instruments. We searched the Global Re-
source of Eczema Trials (GREAT) database for reports 
of randomized controlled trials. Information on patient-
reported outcomes, particularly quality of life, was ex-
tracted from eligible studies. Two-hundred and eighty-
seven full texts reporting on 303 trials and 72 abstracts 
were included. Of the 303 studies, 63 (20.8%) assessed 
quality of life and used 18 named and 4 unnamed instru-
ments. The Dermatology Life Quality Index (DLQI), the 
Children’s Dermatology Life Quality Index (CDLQI), 
the Infants’ Dermatitis Quality of Life Index (IDQOL), 
and the Dermatitis Family Impact (DFI) were the most 
common measures in adults, children, infants, and care-
givers, respectively. In conclusion, only about one fifth 
of eczema trials include a quality of life measure as out-
come. Many different instruments are used, limiting the 
possibilities of comparing and synthesising individual 
trials’ findings. Key words: eczema; atopic dermatitis; 
quality of life; patient-reported outcomes; HOME initia-
tive.
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Eczema (synonym: atopic dermatitis (AD)) is a common 
skin disease that affects both children and adults. It ex-
erts a negative impact on the quality of life (QoL) of the 
patients and their families and places a considerable fi-
nancial burden on patients and society (1, 2). The disease 
is characterized by a chronic or chronically relapsing 
course, with pruritus being the main symptom (3). The 
prevalence of eczema has increased over recent years (4).
Despite a multitude of available treatment options, 
important uncertainties remain in the treatment of ec-
zema requiring the conduct of high quality randomized 
controlled trials (RCTs) (5, 6). The use of non-standar-
dized and inadequately validated outcome measurement 
instruments (OMIs) in eczema trials hampers evidence-
based decision making because treatment effects may be 
over- or underestimated. Furthermore, comparison and 
evidence synthesis is rendered difficult when outcome 
measurement is not standardized.
Therefore, the Harmonising Outcome Measures for 
Eczema (HOME) initiative set out to define a core out-
come set (COS) that should be assessed in all eczema 
trials in the future (7). A COS is a consensus-derived 
minimum set of outcomes to be assessed in a specific 
situation (8). HOME agreed to consider clinical signs, 
symptoms, long term control and QoL as core outcome 
domains (9). For each of these domains an adequate 
OMI needs to be identified. For the signs domain, this 
process has been completed and the Eczema Area and 
Severity Index (EASI) has been identified as the cur-
rently most adequate measurement instrument to assess 
clinical signs in eczema (10).
To standardize processes and to provide a standard 
for COS development in dermatology, the HOME ini-
tiative has published a roadmap (11). According to this 
roadmap, the first step for each core outcome domain 
is a comprehensive review of what OMIs have actually 
been used.
QoL, as one of these core outcome domains, is usu-
ally classified as a patient-reported outcome (PRO). 
A PRO is defined as any report coming directly from 
patients, without interpretation by physicians or others, 
about how they function or feel in relation to a health 
condition and its therapy (12). Where clinical trials use 
a PRO as primary endpoint, this is a reflection of the 
importance that study authors place on PROs. Thus, 
with QoL being a PRO, we hypothesized that authors 
who used PROs as primary endpoints in eczema trials 
would also be more likely to apply QoL questionnaires. 
In accordance with the HOME roadmap (11), the 
primary aim of this systematic review was to identify 
the QoL measurement instruments used in eczema trials 
from the year 2000 onwards. We were also interested 
in whether there were any time trends in their usage. A 
secondary aim was to find out whether the considera-
tion of a PRO as a primary endpoint in eczema trials 
was related to the inclusion of a QoL instrument as an 
outcome measure. 
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METHODS
Sample article selection
To obtain a comprehensive selection of eczema trials, we sear-
ched the Global Resource of Eczema Trials (GREAT) Database 
(13), which includes records of all RCTs of eczema treatments 
(14). An article was considered eligible if it was an eczema tre-
atment trial published since 2000, was indexed in the GREAT 
database by 31 May 2014 and if a full text or an abstract was av-
ailable in either English or German language. We did not consider 
any other sources of eczema trials besides the GREAT database.
Outcomes
The outcomes of interest were: i) the proportion of articles that 
assessed a QoL outcome, ii) the proportion of articles that as-
sessed a PRO, iii) whether the inclusion of a QoL measure was 
related to whether the primary endpoint was a PRO, iv) what 
QoL instruments were used, v) the number of QoL instruments 
per study and vi) the number of studies published and the pro-
portion including QoL instruments over time. 
A patient-reported outcome (PRO) was defined according to 
Patrick et al. (12) as any report coming directly from patients, 
without interpretation by physicians or others, about how they 
function or feel in relation to a health condition and its therapy. 
Any outcome used in the included studies that fulfilled this 
definition was recorded as a PRO. We did not categorize PROs 
according to content or type. The term ‘composite index’ was 
used to describe any score or index that is composed of both a 
PRO and a non-PRO part. 
Data extraction
Data extraction was carried out by D.H. To ensure consistency 
in the data extraction, guidelines on what information should 
be gathered and how this information should be evaluated was 
agreed on beforehand by D.H. and C.A. Where these guidelines 
were not applicable to certain studies, the whole team decided 
about how to evaluate the information from those studies. A 
second data extraction was performed for a random sample of 
10% of the papers by J.C. as a measure of quality assurance. 
For this sample, results were compared between the first and 
the second data extraction and discrepancies were resolved 
within the whole team. Where a resolution of a discrepancy 
within this random sample meant that changes were necessary 
to the initially extracted information by D.H., these changes 
were also made in the data extractions of the rest of the studies 
where applicable. Where the study was reported only in an 
abstract, only data on QoL was extracted.
Data analysis
Statistical data analysis was split into a descriptive and an 
analytical part.
Descriptive analysis
We determined the absolute number and the percentage of ar-
ticles assessing QoL. To get an overview of the most common 
QoL measures, we recorded which questionnaires were used 
by how many studies. Moreover, we determined the number 
of QoL instruments used per article (only regarding articles 
which assessed QoL) and explored changes in the usage of QoL 
measures over time, which we visualized in diagrams created 
with Microsoft Excel. 
We also calculated the proportion of PROs (with/without 
composite indices) in relation to all outcomes, the absolute 
number and percentage of articles assessing PROs (with/wit-
hout composite indices) in relation to all articles, the median 
number (and interquartile range (IQR)) of outcomes per article, 
the median number (and IQR) of PROs per article (with/without 
composite indices; only regarding articles which assess PROs) 
and the number of composite indices per article (only regarding 
articles which assess composite indices). Furthermore, we 
analysed changes in the total number of outcomes over time 
and depicted our findings in a diagram.
Analytical analysis
We hypothesized that authors who are generally in sympathy 
with the integration of PROs in eczema trials would also be 
more likely to apply QoL questionnaires. Therefore, we com-
puted the absolute and relative frequency of articles assessing 
QoL in articles with PROs as primary endpoint, in articles with 
composite indices as primary endpoint, in articles which did not 
specify their primary endpoint and in articles with non-PROs 
as primary endpoint. A chi-square test was conducted to test 
our hypothesis about the connection between a study’s primary 
endpoint and QoL assessment. The results of this chi-square test 
were presented in a contingency table. Level of significance 
was set at 5%.
For all analyses, IbM SPSS 22.0 was used. Data was extracted 
and figures were designed with Microsoft Excel 2013. We used 
Endnote X6 to manage references.
RESULTS
Our search yielded 378 papers that were published 
since 2000 and indexed in the GREAT database by no 
later than 31 May 2014. References to these papers can 
be found in Appendix S11. nineteen articles were not 
eligible. The reasons for exclusion were: paper was 
protocol only (n = 9), no English or German abstract 
or full text was available (n = 5), paper reported on a 
study already included (n = 4), paper was conference 
publication and not available as abstract or full text 
(n = 1). Of the 359 eligible articles, we were able to 
obtain the full text for 287 papers, and an abstract only 
for the remaining 72 articles. The 287 full text papers 
reported on 303 studies. The distribution of publica-
tions over time is shown in Fig. 1. As can be seen from 
Fig. 1, 2011 saw the highest number of trials. Despite 
some minor differences, similar numbers of studies 
were found eligible for every publication year.
Descriptive analysis
Overall, only 63 (20.8%) studies assessed QoL. The 
QoL instruments that were applied in these studies are 
listed in Table I for adults and children and families, 
respectively. In adults, the Dermatology Life Quality 
Index (DLQI) (15) was the most frequently used self-
reported QoL measure; in children, the Children’s 
Dermatology Life Quality Index (CDLQI) (16) was 
the most popular self-reported questionnaire and the 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2322
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Infants’ Dermatitis Quality of Life Index (IDQOL) 
(17) was the proxy-reported instrument most often 
used. QoL of carers of children was predominantly 
assessed with the Dermatitis Family Impact (DFI) 
questionnaire (18). Altogether, 18 named and 4 unna-
med QoL questionnaires were used; of these, 4 were 
infant- or children-specific measures, 4 assessed the 
QoL of carers and 16 instruments were applicable to 
adult patients with eczema. Six instruments, 4 of which 
are validated, were eczema-specific.
Of the 63 trials that assessed QoL, we found that the 
majority of studies (n = 41, 65.1%) used only one QoL 
measurement instrument. Two QoL instruments were 
applied in 16 studies (25.4%) and the remaining 6 stu-
dies (9.5%) included 3 QoL measurement instruments. 
Analysis over time showed that although there were 
fluctuations from year to year, the proportion of trials 
that include QoL measures has remained largely static 
since 2000 (Fig. 2). For instance, none of the 22 studies 
that were published in 2005 included a QoL instrument 
whereas studies from 2006 with an inclusion rate of 
QoL measurement instruments of 31% are even above 
average. The highest percentage of studies assessing 
QoL (50%) was observed in 2014; however, this finding 
needs to be put into context as only 4 studies from 2014 
were included in total.
Similarly, we could not observe any clear trends 
towards increased or reduced usage of the most fre-
quently applied specific QoL instruments (Fig. S11). 
In most years, less than 10% of the included full texts 
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Fig. 1. Distribution of included full text studies over time.
Table I. Quality of life instruments used in adults and children and families/carers
Instrument, Ref.
Studies 
n (%), Ref. Type Full name
Adults (n = 36)
DLQI (15) 20 (56) (19–38) Dermatology-specific Dermatology Life Quality Index
Skindex-29 (39) 2 (6) (40, 41) Dermatology-specific
EDLQ (42) 1 (3) (43) Generic Everyday Life Questionnaire/Alltagsleben
EQ-5D (44) 1 (3) (45) Generic EuroQoL-5D
SF-36 (46) 1 (3) (47) Generic Short form 36
SIP (48) 1 (3) (49) Generic Sickness Impact Profile
WTP (50) 1 (3) (49) Generic Willingness To Pay
DIELH (51) 1 (3) (52) Dermatology-specific Deutsches Instrument zur Erfassung der 
Lebensqualität bei Hauterkrankungen
DLQI (modified)* (15) 1 (3) (53) Dermatology-specific Dermatology Life Quality Index
FLQA-d (54) 1 (3) (49) Dermatology-specific Freiburg Life Quality Assessment for Dermatoses
ISDL (modified)* (55) 1 (3) (36) Dermatology-specific Impact of Chronic Skin Disease on Daily Life
Self-provided* 1 (3) (56) Dermatology-specific Unnamed
Skindex-16 (57) 1 (3) (58) Dermatology-specific
Skindex-17 (59) 1 (3) (60) Dermatology-specific
EDI* (61) 1 (3) (62) Eczema-specific Eczema Disability Index
QoLIAD (63) 1 (3) (26) Eczema-specific Quality of Life Index for Atopic Dermatitis
Children and families/carers
Proxy-reported instrumentsa (n = 15)
IDQOL (17) 14 (93) (36, 64–76) Eczema-specific Infants’ Dermatitis Quality of Life Index
Self-provided* 1 (7) (77) Eczema-specific Unnamed
Self-reported instrumentsb (n = 20)
CDLQI (16) 18 (90) (28, 65, 69, 72–75, 78–88) Dermatology-specific Children’s Dermatology Life Quality Index
CDLQI (modified)* (16) 2 (10) (89, 90) Dermatology-specific Children’s Dermatology Life Quality Index
Instruments assessing the quality of life of adult carers of children with eczema (n = 20)
DFI (18) 14 (70) (45, 64–67, 69–73, 81, 86, 
87, 91)
Dermatology-specific Dermatitis Family Impact
Questionnaire by Rüden et al. (92) 3 (15) (43, 93, 94) Eczema-specific Unnamed
PIQoL-AD (95) 2 (10) (88, 96) Eczema-specific Parents’ Index of Quality of Life in Atopic Dermatitis
Self-provided* 1 (5) (83) Unknown Unnamed
*Instruments marked with an asterisk have not been validated at all.
aProxy-reported means that the (primary) caregiver of an infant fills in a questionnaire that assesses the quality of life of the infant. Proxy-reported instruments 
are often used in infants and younger children because they cannot report on their quality of life themselves due to their inability to read and a lack of 
understanding. bSelf-reported instruments are used in older children. These questionnaires are filled in by the children themselves, not by their caregiver.
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applied the DLQI (15), the IDQOL (17), the CDLQI 
(16) or the DFI (18). In 2014, 25% of the included full 
texts used the 4 instruments depicted in Fig. S11; how-
ever, this result should not be interpreted as a recent rise 
in usage of these measures since only 4 full texts from 
2014 were included in our systematic review.
For the studies which were reported in abstract form 
only, only 4 out of 72 (6%) assessed QoL. The CDLQI 
(16) was used in 2 abstracts and the DFI (18) in 1 ab-
stract. Three further QoL instruments were reported, 
but were not named.
The assessment of the full text articles revealed that 
a total of 2,633 outcomes were assessed of which 809 
(30.7%) were PROs or composite indices (i.e. a scale 
that is composed of both a PRO and a non-PRO part). 
Of these, 633 (24.0%) were PROs and 176 (6.7%) 
were composite indices. The majority of studies (281, 
92.7%) included at least one PRO and/or a composite 
index as any endpoint (primary, secondary, other). A 
total of 230 (85.9%) studies included at least one PRO, 
whereas composite indices were assessed in just over 
half of studies (164, 54.1%). 
The median number of outcomes per study was 7 
(IQR: 5–11). In studies that assessed PROs and/or 
composite indices, the median number of PROs was 2 
(IQR 1–4). The same values were found when looking 
at PROs without composite indices. For studies using 
composite indices, the vast majority of 153 (93.3%) 
studies included only one composite index, 10 studies 
(6.1%) two composite indices and only a single study 
applied 3 composite indices. Analysis over time sho-
wed that the median number of outcomes per study has 
plateaued since 2000. The highest median number of 
outcomes per study was 9.5 in 2006 whereas the lowest 
number was 5 in 2013. A median of 6 outcomes was 
found for 4 years; the same is true for a median of 7 
outcomes. In 3 years, the median number of outcomes 
per study amounted to 8.
Analytical analysis
We were able to categorise the endpoints for 302 stu-
dies: 32 studies (10.6%) chose a PRO as primary end-
point, 58 trials (19.2%) a composite index, 81 studies 
(26.8%) had a non-PRO as primary endpoint and 131 
studies (43.4%) did not specify their primary endpoint. 
The endpoint for one study could not be categorised.
There was a statistically significant association bet-
ween the type of primary endpoint (PRO, composite 
index, non-PRO, not specified) and the assessment of 
QoL (yes/no) (p = 0.002, Table II). Studies with a PRO 
as primary endpoint were most likely to measure QoL, 
followed by studies with a composite index as primary 
endpoint. Likewise, study authors that used a distinct 
non-PRO as primary endpoint were more likely to in-
clude QoL measurement than study authors that did not 
specify their primary endpoint in more detail.
DISCUSSIOn
QoL is considered particularly relevant for chronic skin 
diseases such as eczema. Inclusion of QoL instruments 
in RCTs is of great importance, given the fact that the 
patient’s perspective on the efficacy of a certain treat-
ment often deviates from clinicians’ assessments (97).
Our study demonstrated that the majority of studies 
(approximately 90%) include at least one PRO. This is 
in contrast to previous findings that only about 25% of 
dermatology trials included a participant efficacy out-
come (98). However, we did not apply any limitations 
concerning the type of PRO which may explain these 
differences. Despite the fact that most studies included 
a PRO, it was clear from this review that the majority 
of outcomes (approximately three-quarters) reported 
are non-PROs. 
Even though the QoL of patients and their family is 
greatly impacted by eczema, respective outcome mea-
sures often seem to only play a minor part in eczema 
trials (99). One study, however, noted a substantial in-
crease in the usage of QoL instruments in eczema trials 
from 1985 to 2010 (100). We were not able to verify 
this trend since our findings suggest that the inclusion 
of QoL measurement instruments has changed very 
little over time. A reason for this result may be that we 
looked at the relative frequency of studies assessing 
QoL instead of absolute numbers, taking into account 
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Fig. 2. Percentage of studies assessing quality of life (QoL) over time. n: 
total number of included studies in the respective year.
Table II. Association between primary endpoint and assessment 
of quality of life 
Primary endpoint
TotalPRO
Composite 
Index non-PRO
not 
specified
Quality of Life assessed?
Yes, n (%) 14 (43.8) 14 (24.1) 17 (21.0) 18 (13.7) 63 (20.9)
no, n (%) 18 (56.3) 44 (75.9) 64 (79.0) 113 (86.3) 239 (79.1)
Total, n (%) 32 (100) 58 (100) 81 (100) 131 (100) 302 (100)
X²=14.556, p = 0.002. 
PRO: Patient-reported outcome.
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the larger quantity of trials in our observation period, 
compared to the observation period investigated by Re-
hal & Armstrong (100). Different time intervals in that 
study and our review may present a further explanation 
of this discrepancy since the idea of QoL in dermatology 
emerged in the early 1990s and the development of the 
first QoL instruments for dermatological conditions 
falls also in this time period. Consequently, a broader 
inclusion of QoL measurement instruments in trials 
did not start until the late 1990s. Rehal & Armstrong 
(100) reported that 14 different QoL instruments were 
used in eczema trials from 1985 to 2010. In contrast, 
we found that from 2000 to 2014, study authors applied 
22 different instruments, suggesting a growing number 
of existing QoL OMIs. Nonetheless, findings on the 
most frequently applied QoL instruments were similar 
in both reviews.
The QoL instruments that were mostly used in clinical 
trials, i.e. the DLQI (15), the IDQOL (17), the CDLQI 
(16) and the DFI (18), all have been developed at 
one academic medical centre (see http://www.cardiff.
ac.uk/dermatology/quality-of-life/). Reasons for the 
widespread use of these instruments may be that they 
are available in many language versions and that they 
are easy to use. All 4 instruments fit on one A4 page 
whereas other questionnaires are often longer. A critical 
review recommends the Skindex-29 (39) rather than the 
DLQI as dermatology-specific QoL measure (101), but 
we identified only 2 trials in which it was actually used.
With respect to the lack of “hard” outcomes such as 
mortality in eczema, QoL measures could fill this gap 
and provide the necessary evidence to judge the ef-
fectiveness and appropriateness of interventions from 
the patients’ perspective. Against this backdrop, it is 
surprising that only 1 out of 5 eczema trials include 
QoL instruments, particularly since similar figures are 
obtained for different diseases in other fields of medi-
cine. For example, one study found that 16% of drug 
clinical trials published in 2005 in 5 high quality jour-
nals included QoL measures (102). However, most of 
these studies reported on heart disease, cancer or other 
serious illnesses where “hard” outcomes are available. 
Authors of future eczema trials should therefore consi-
der the inclusion of a QoL measurement in their trials. 
We could show that authors who chose PROs as 
primary endpoints in their trials were also more likely 
to include QoL measures than researchers that decided 
to use any other endpoints. Surprisingly, this observa-
tion holds also for composite indices: A significantly 
higher proportion of studies with a composite index as 
primary endpoint assessed QoL than did studies with a 
non-PRO or a not specified endpoint. This implies that 
the measurement of QoL is not so much dependent on 
individual characteristics of a trial when opting for or 
against the inclusion of QoL instruments; instead, the 
general attitude of study authors towards PROs appears 
to determine whether or not QoL is measured as well. 
In addition, this finding may also explain why there 
was no increase in QoL measurement over time despite 
ongoing efforts to promote the use of QoL instruments. 
Moreover, there seems to be an association between 
how well researchers report on their study results and 
the measurement of QoL since authors that did not 
specify their primary endpoint were least likely to use 
QoL instruments. However, further research is war-
ranted to find out why QoL measurement instruments 
are not included in more trials.
Some further attention must also be drawn to the high 
proportion of studies that did not specify their primary 
endpoint (43.4%). In contrast, nassar et al. (103) found 
that only 20% of the RCTs on non-neoplastic skin di-
seases that were published in 2009 did not state their 
primary outcome. However, they restricted their search 
to journals with an impact factor of at least 2. As they 
also showed that a clear definition of the primary end-
point was significantly associated with a higher journal 
impact factor, this result may present an explanation 
for our findings because we did not narrow down our 
eligibility criteria to high quality journals.
In conclusion, we could demonstrate that a high 
proportion of trials include some sort of PROs but that 
QoL was only assessed in about one fifth of all trials. 
Even though a range of QoL measurement instruments 
have been used in RCTs of eczema, most studies applied 
the DLQI (15) for adults, the CDLQI (16) for older 
children, the IDQOL (17) for infants or the DFI (18) 
for adult carers of children with eczema. 
We provide an up-to-date review on QoL OMIs used 
for eczema. A strength of this study was the use of the 
GREAT database, which searches 6 databases, including 
3 specialist databases. A recent study showed a high sen-
sitivity of the GREAT database, with 94% of trials cited 
in systematic reviews on eczema treatments listed in the 
GREAT database (104). The GREAT database therefore 
is considered a primary and comprehensive source to 
identify eczema RCTs. We did not consider any other 
study designs for inclusion in this systematic review.
Limitations of our study were the language restric-
tion to English and German and our focus on the time 
interval from 2000 to 2014. In this way, QoL ques-
tionnaires in other languages may have been missed 
or underestimated and older QoL instruments may 
be underrepresented in our review. Also, we did not 
consider ongoing trials for this review. As a result, we 
cannot rule out the possibility that different findings 
would be obtained when regarding studies that are 
currently under way.
Results on the number of reported outcomes, the 
number of reported PROs, the number of reported 
composite indices, the proportion of validated indices 
used, the assessment of adverse events and additional 
safety assessments will be reported elsewhere.
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The aim of this systematic review was not to critically 
appraise the measurement properties of the available 
QoL scales for eczema patients. Instead, this syste-
matic review is intended to form the basis for further 
research on the appropriateness of the mentioned QoL 
instruments for eczema patients. As the use of so many 
different QoL instruments in eczema trials limits the 
possibility to synthesize their findings in meta-analyses 
and systematic reviews, the HOME initiative aims to 
define a COS including one distinct QoL instrument. 
A critical appraisal of the measurement properties of 
existing QoL instruments is the prerequisite for doing so 
and will be subject to a further systematic review. Our 
review is the first step to reach the goal of including a 
QoL instrument in the COS.
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Fig. S1. Percentage of included full texts using one of the 4 most frequently applied quality of life (QoL) instruments 
over time. DLQI: Dermatology Life Quality Index; IDQOL: Infants’ Dermatitis Quality of Life Index; CDLQI: 
Children’s Dermatology Life Quality Index; DFI: Dermatitis Family Impact.
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